Symmetrix names new chief scientific officer

Dr Shebuski, a cardiovascular pharmacologist, has broad experience in cardiovascular drug development with over 25 years in the pharmaceutical industry. He will be responsible for the pre-clinical and clinical development of SMRX 11 under the direction of Yatindra Prashar, president and CEO of Symmetrix, pursuant to a contract with Symmetrix Biotech.

Previously, Dr Shebuski was the vice president of research for Afmedica, which developed a drug-eluting medical device that was acquired by Angiotech Pharmaceuticals. Prior to that he directed the Cardiovascular Therapeutics Group at Pharmacia & Upjohn where he managed the team responsible for FDA approval of the class III anti-arrhythmic agent, Corvert.

Dr Shebuski is an adjunct associate professor of pharmacology and professor of integrative biology and physiology at the University of Minnesota Medical School. He received his BS degree in microbiology from the University of Wisconsin-Madison and PhD degree in pharmacology from the University of Minnesota Medical School in Minneapolis.

Nirmal Mulye, president and founder of Nostrum Pharmaceuticals, said: “I am very pleased and excited to have a scientist and professional of Dr Shebuski’s caliber joining the Nostrum team.”